Citations

Clear

16281 citation(s) found for "Yu, David".

Validation of Noninvasive Detection of Hyperkalemia by Artificial Intelligence–Enhanced Electrocardiography in High Acuity Settings
Harmon, David , Dugan, Jennifer , Jentzer, Jacob C. , Attia, Zachi I. , Friedman, Paul A. , Dillon, John , Harmon, David M , Liu, Kan , Dugan, Jennifer , Jentzer, Jacob C , Attia, Zachi I , Dillon, John J

Mayo Clinic

Clinical Journal of the American Society of Nephrology | June 21, 2024 | Volume: 19 | Issue: 8 | Pages: 952-958

10.2215/cjn.0000000000000483 | PMID 39116276 Get It

Key Points Measuring blood potassium has always required access to blood. The surface electrocardiogram, analyzed using an artificial intelligence algorithm, can detect hyperkalemia bloodlessly. The artificial intelligence-analyzed electrocardiogram exhibited a high negative predictive value but substantially lower positive predictive value. Background Artificial intelligence (AI) electrocardiogram (ECG) analysis can enable detection of hyperkalemia. In this validation, we assessed the algorithm's performance in two high acuity settings. Methods An emergency department (ED) cohort (February to August 2021) and a mixed intensive care unit (ICU) cohort (August 2017 to February 2018) were identified and analyzed separately. For each group, pairs of laboratory-collected potassium and 12 lead ECGs obtained within 4 hours of each other were identified. The previously developed AI ECG algorithm was subsequently applied to leads 1 and 2 of the 12 lead ECGs to screen for hyperkalemia (potassium >6.0 mEq/L). Results The ED cohort ( N =40,128) had a mean age of 60 years, 48% were male, and 1% ( N =351) had hyperkalemia. The area under the curve (AUC) of the AI-enhanced ECG (AI-ECG) to detect hyperkalemia was 0.88, with sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive likelihood ratio (LR+) of 80%, 80%, 3%, 99.8%, and 4.0, respectively, in the ED cohort. Low-eGFR (<30 ml/min) subanalysis yielded AUC, sensitivity, specificity, PPV, NPV, and LR+ of 0.83, 86%, 60%, 15%, 98%, and 2.2, respectively, in the ED cohort. The ICU cohort ( N =2636) had a mean age of 65 years, 60% were male, and 3% ( N =87) had hyperkalemia. The AUC for the AI-ECG was 0.88 and yielded sensitivity, specificity, PPV, NPV, and LR+ of 82%, 82%, 14%, 99%, and 4.6, respectively in the ICU cohort. Low-eGFR subanalysis yielded AUC, sensitivity, specificity, PPV, NPV, and LR+ of 0.85, 88%, 67%, 29%, 97%, and 2.7, respectively in the ICU cohort. Conclusions The AI-ECG algorithm demonstrated a high NPV, suggesting that it is useful for ruling out hyperkalemia, but a low PPV, suggesting that it is insufficient for treating hyperkalemia.
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
Patel‐Murray, Natasha , Zhang, Luqing , Claggett, Brian , Xu, Dongchu , Serrano‐Fernández, Pablo , Healey, Margaret L. , Wandel, Simon , Jacob, Jaison , Xu, Huilei , Chutkow, William A., O’Donnell, Christopher J. , Prescott, Margaret F., Lefkowitz, Marty , Gimpelewicz, Claudio , Zhao, Faye, Gou, Liangke , Redfield, Margaret M. , Rouleau, Jean L. , Zannad, Faı̈ez , Solomon, Scott D. , Patel-Murray, Natasha L , Claggett, Brian L , Healey, Margaret , Jacob, Jaison , Xu, Huilei , Turner, Gordon M , Yates, Denise P , O'Donnell, Christopher J , Lefkowitz, Martin P , Gimpelewicz, Claudio R , Beste, Michael T , Gou, Liangke , Desai, Akshay S , Jhund, Pardeep S , Packer, Milton , Pfeffer, Marc Alan , Redfield, Margaret M , Rouleau, Jean L , Zannad, Faiez , Zile, Michael R , McMurray, John J V , Mendelson, Michael M , Solomon, Scott David , Cunningham, Jonathan W , Chen, Chien‐Wei , Jhund, Pardeep S. , Packer, Milton , Zile, Michael R. , McMurray, John J.V. , Cunningham, Jonathan W.

Mayo Clinic

Journal of the American Heart Association | June 21, 2024 | Volume: 13 | Issue: 13 | Pages: No page available

10.1161/jaha.123.033544 | PMID 38904251 Get It

Background Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Methods and Results We measured serum levels of 4123 unique proteins in 1117 patients with HFpEF enrolled in the PARAGON‐HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial using a modified aptamer proteomic assay. Baseline circulating protein concentrations significantly associated with the primary end point and the timing and occurrence of total heart failure hospitalization and cardiovascular death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared with published analyses in 2515 patients with heart failure with reduced ejection fraction from the PARADIGM‐HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and ATMOSPHERE (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity–Mortality in Patients With Chronic Heart Failure) clinical trials. We identified 288 proteins that were robustly associated with the risk of heart failure hospitalization and cardiovascular death in patients with HFpEF. The baseline proteins most strongly related to outcomes included B2M (β‐2 microglobulin), TIMP1 (tissue inhibitor of matrix metalloproteinase 1), SERPINA4 (serpin family A member 4), and SVEP1 (sushi, von Willebrand factor type A, EGF, and pentraxin domain containing 1). Overall, the protein–outcome associations in patients with HFpEF did not markedly differ as compared with patients with heart failure with reduced ejection fraction. A proteomic risk score derived in patients with HFpEF was not superior to a previous proteomic score derived in heart failure with reduced ejection fraction nor to clinical risk factors, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), or high‐sensitivity cardiac troponin. Conclusions Numerous serum proteins linked to metabolic, coagulation, and extracellular matrix regulatory pathways were associated with worse HFpEF prognosis in the PARAGON‐HF proteomic substudy. Our results demonstrate substantial similarities among serum proteomic risk markers for heart failure hospitalization and cardiovascular death when comparing clinical trial participants with heart failure across the ejection fraction spectrum. Registration URL: https://www.clinicaltrials.gov ; Unique Identifiers: NCT01920711, NCT01035255, NCT00853658.
Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention
Mahmoud, Ahmed , Awad, Kamal , Ali, Nima Baba , Pereyra, Milagros , Scalia, Isabel G. , Allam, Mohamed, Kamel, Moaz, Rmilah, Anan Abu , Chao, Chieh-Ju, Barry, Timothy, Lester, Steven J., Pollak, Peter , Sweeney, John P., Fortuin, David, Arsanjani, Reza , Mahmoud, Ahmed K , Allam, Mohamed N , Kamel, Moaz A, Alsidawi, Said , Pollak, Peter M, Alkhouli, Mohamad A, Lee, Richard W, Fortuin, David F, Arsanjani, Reza , Pereyra, Milagros , Scalia, Isabel G , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Allam, Mohamed N, Chao, Chieh‐Ju , Alsidawi, Said , Alkhouli, Mohamad , Lee, Kwan , Yang, Eric H. , Lee, Richard

Mayo Clinic

European Journal of Preventive Cardiology | June 20, 2024 | Volume: 31 | Issue: 15 | Pages: 1878-1887

10.1093/eurjpc/zwae212 | PMID 38916491 Get It

Abstract Aims Lipoprotein(a) [Lp(a)] has demonstrated its association with atherosclerosis and myocardial infarction. However, its role in the development of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) is not clearly established. The aim of this study is to investigate the association between Lp(a) and ISR. Methods and results A retrospective study of adult patients who underwent successful PCI between January 2006 and December 2017 at the three Mayo Clinic sites and had a preprocedural Lp(a) measurement was conducted. Patients were divided into two groups according to the serum Lp(a) concentration [high Lp(a) ≥ 50 mg/dL and low Lp(a) &lt; 50 mg/dL]. Univariable and multivariable analyses were performed to compare risk of ISR between patients with high Lp(a) vs. those with low Lp(a). A total of 1209 patients were included, with mean age 65.9 ± 11.7 years and 71.8% were male. Median follow-up after baseline PCI was 8.8 [interquartile range (IQR) 7.4] years. Restenosis was observed in 162 (13.4%) patients. Median serum levels of Lp(a) were significantly higher in patients affected by ISR vs. non-affected cases: 27 (IQR 73.8) vs. 20 (IQR 57.5) mg/dL, P = 0.008. The rate of ISR was significantly higher among patients with high Lp(a) vs. patients with low Lp(a) values (17.0% vs. 11.6%, P = 0.010). High Lp(a) values were independently associated with ISR events (hazard ratio 1.67, 95% confidence interval 1.18–2.37, P = 0.004), and this association was more prominent after the first year following the PCI. Conclusion Lipoprotein(a) is an independent predictor for long-term ISR and should be considered in the evaluation of patients undergoing PCI.
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Ljungman, Per , Chemaly, Roy F. , Khawaya, Fareed, Badshah, Cyrus, Boeckh, Michael, Fournier, Martha , Hodowanec, Aimee , Komatsu, Takashi , Manuel, Oriol , Pikis, Andreas, Westman, Gabriel , Griffiths, Paul , Kotton, Camille N. , Forum, for the CMV Definitions Working Group of the Transplant Associated Virus Infections, Komatsu, Takashi, Piki, Andreas, Westman, Gabriel, Caliendo, Angie, Chou, Sunwen, Humar, Atul , Wong, Michelle , Wolf, Dana G. , Razonable, Raymund R , Alain, Sophie , Avery, Robin K , Boeckh, Michael , Limaye, Ajit P. , Natori, Yoichiro , Navarro, David , Razonable, Raymund R. , Miller, Veronica , Forum, for the CMV Definitions Working Group of the Transplant Associated Virus Infections, Komatsu, Takashi, Westman, Gabriel, Randhawa, Parmjeet Singh , Slavin, Monica A. , Wong, Michelle

Mayo Clinic

Clinical Infectious Diseases | June 20, 2024 | Volume: 79 | Issue: 3 | Pages: 787-794

10.1093/cid/ciae321 | PMID 39041385 Get It

Abstract Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians, regulators, and industry representatives, has produced an updated version of these definitions that incorporates recent knowledge with the aim of supporting clinical research and drug development. This also includes an update regarding the definition of resistant and refractory CMV infections previously published in 2019. As the field evolves, the need for updates of these definitions is clear, and collaborative efforts among clinicians, scientists, regulators, and industry representatives can provide a platform for this work.
Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective Interventions
Boehmer, Kasey R. , LaVecchia, Christina M. , Sharma, Vidit , Schulte, Phillip J. , Tilburt, Jon C. , Boorjian, Stephen A. , Kamath, Celia C , Joyce, Daniel , Kamath, Celia , Penson, David F.

Mayo Clinic

Urology Practice | June 20, 2024 | Volume: 11 | Issue: 4 | Pages: 640-652

10.1097/upj.0000000000000589 | PMID 38899638 Get It

Exercise intervention may play a potential therapeutic role in patients with glioblastoma multiforme (Review)
Sharif, Salaheddin, Harman, Nicholas, Hydock, David S., Olson, Thomas P. , Sharif, Salaheddin M.

Mayo Clinic

World Academy of Sciences Journal | June 20, 2024 | Volume: 6 | Issue: 5 | Pages: No page available

10.3892/wasj.2024.256 Get It

Liver disease and transplantation in telomere biology disorders: An international multicenter cohort
Kaj‐Carbaidwala, Batul , Lane, Adam , Agarwal, Suneet , Bertuch, Alison A. , Borovsky, Kristin A., Dufour, Carlo , Fioredda, Francesca , Giri, Neelam , Goldman, Frederick D. , Hertel, Paula M. , Keel, Sioḃán , Koura, Divya, Kratz, Christian P. , Liou, Iris, Nakano, Taizo A. , Nastasio, Silvia , Sasa, Ghadir , Miethke, Alexander , Penrice, Daniel D. , Wang, YunZu Michele , Beier, Fabian , Borovsky, Kristin A., Brennan, Steven K. , Calado, Rodrigo T. , Catto, Luiz Fernando Bazzo , Ebens, Christen L. , Gloude, Nicholas Joseph , Himes, Ryan , Kulkarni, Sakil S , Niewisch, Marena Rebekka , Savage, Sharon A. , Simonetto, Douglas A. , Ziegler, David Simon , Myers, Kasiani

Mayo Clinic

Hepatology Communications | June 19, 2024 | Volume: 8 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000462 | PMID 38896081 Get It

Background: Patients with telomere biology disorders (TBD) develop hepatic disease, including hepatitis, cirrhosis, and hepatopulmonary syndrome. No specific treatment exists for TBD-related liver disease, and the role of liver transplantation (LT) remains controversial. Our study objectives were to describe the clinical characteristics, management, and outcomes in patients with TBD-related liver disease, and their LT outcomes. Methods: Data from 83 patients with TBD-associated liver disease were obtained from 17 participating centers in the Clinical Care Consortium of Telomere-Associated Ailments and by self-report for our retrospective, multicenter, international cohort study. Results: Group A (“Advanced”) included 40 patients with advanced liver disease. Of these, 20 underwent LT (Group A T ). Group M (“Mild”) included 43 patients not warranting LT evaluation, none of whom were felt to be medically unfit for liver transplantation. Supplemental oxygen requirement, pulmonary arteriovenous malformation, hepatopulmonary syndrome, and higher bilirubin and international normalized ratio values were associated with Group A. Other demographics, clinical manifestations, and laboratory findings were similar between groups. Six group A patients were declined for LT; 3 died on the waitlist. Median follow-up post-LT was 2.9 years (range 0.6–13.2 y). One-year survival post-LT was 73%. Median survival post-LT has not been reached. Group A T patients had improved survival by age compared to all nontransplant patients (log-rank test p = 0.02). Of 14 patients with pretransplant hypoxemia, 8 (57%) had improved oxygenation after transplant. Conclusions: LT recipients with TBD do not exhibit excessive posttransplant mortality, and LT improved respiratory status in 57%. A TBD diagnosis should not exclude LT consideration.
KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis
Sigafoos, Ashley N. , Tolosa, Ezequiel J. , Carr, Ryan M. , Fernández‐Barrena, Maite G. , Almada, Luciana L. , Pease, David R. , Hogenson, Tara L. , Arul, Glancis L. Raja , Mousavi, Fatemeh , Sen, Sandhya , Vera, Renzo E., Marks, David L. , Flores, Luis F. , LaRue-Nolan, Kayla C. , Wu, Chen , Vrabel, Anne M., Sicotte, Hugues , Smyrk, Thomas C. , Zhang, Lizhi , Oberg, Ann L. , Elsawa, Sherine F. , Pin, Christopher L. , Mao, Junhao , Fernández-Zapico, Martín E. , Raja Arul, Glancis L, Bamlet, William R , Sicotte, Hugues , Schenk, Erin L. , Chaffee, Kari G. , Oberg, Ann L , Chevet, Eric , Graham, Rondell P , Hagen, Catherine E , McWilliams, Robert R , Fernandez-Zapico, Martin E , Elsawa, Sherine F , Raja Arul, Glancis Luzeena , Carr, Ryan M , Bamlet, William R. , Rabe, Kari G. , Zaphiropoulos, Peter G. , Chevet, Éric , Graham, Rondell P. , Hagen, Catherine E. , Magliano, Marina Pasca di , McWilliams, Robert R.

Mayo Clinic

Cancer Research Communications | June 19, 2024 | Volume: 4 | Issue: 7 | Pages: 1677-1689

10.1158/2767-9764.crc-23-0464 | PMID 38896052 Get It

Abstract Aberrant activation of GLI transcription factors has been implicated in the pathogenesis of different tumor types including pancreatic ductal adenocarcinoma. However, the mechanistic link with established drivers of this disease remains in part elusive. In this study, using a new genetically engineered mouse model overexpressing constitutively active mouse form of GLI2 and a combination of genome-wide assays, we provide evidence of a novel mechanism underlying the interplay between KRAS, a major driver of pancreatic ductal adenocarcinoma development, and GLI2 to control oncogenic gene expression. These mice, also expressing KrasG12D, show significantly reduced median survival rate and accelerated tumorigenesis compared with the KrasG12D only expressing mice. Analysis of the mechanism using RNA sequencing demonstrate higher levels of GLI2 targets, particularly tumor growth–promoting genes, including Ccnd1, N-Myc, and Bcl2, in KrasG12D mutant cells. Furthermore, chromatin immunoprecipitation sequencing studies showed that in these cells KrasG12D increases the levels of trimethylation of lysine 4 of the histone 3 (H3K4me3) at the promoter of GLI2 targets without affecting significantly the levels of other major active chromatin marks. Importantly, Gli2 knockdown reduces H3K4me3 enrichment and gene expression induced by mutant Kras. In summary, we demonstrate that Gli2 plays a significant role in pancreatic carcinogenesis by acting as a downstream effector of KrasG12D to control gene expression.
Impact of Obesity on Timing of Tracheotomy: A Multi‐institutional Retrospective Study
Yousef, Andrew , Soliman, Shady , Panuganti, Bharat , Francis, David O. , Klebaner, Dasha, Asturias, Alicia , Alattar, Ali , Wood, Samuel , Terry, M. C. , Bryson, Paul C. , Tipton, Courtney B. , Zhao, Elise E. , Maria, Chloe Santa , Sung, C. Kwang , Lao, Wilson P. , Thompson, Jordan M. , Crawley, Brianna K. , Rosen, Sarah P. , Berezovsky, Anna , Hennesy, Theresa B. , Joseph, Ian T. , Sarhadi, Kamron, Kuhn, Maggie A. , Abdel‐Aty, Yassmeen , Kennedy, Maeve M. , Weissbrod, Philip A. , Soliman, Shady I , Pang, John , Wood, Samuel , Terry, Morgan , O'Rourke, Ashli , Grimm, David R , Sung, C K , Crawley, Brianna K , Rosen, Sarah , Berezovsky, Anna , Clary, Matthew S , Abdel-Aty, Yassmeen, Lott, David G , Weissbrod, Philip A , Solomon, Isaac, Grimm, David R. , Kupfer, Robbi A. , Clary, Matthew S. , Lott, David G.

Mayo Clinic

The Laryngoscope | June 19, 2024 | Volume: 134 | Issue: 11 | Pages: 4674-4681

10.1002/lary.31586 | PMID 38895915 Get It

Objective To examine the impact of increased body mass index (BMI) on (1) tracheotomy timing and (2) short‐term surgical complications requiring a return to the operating room and 30‐day mortality utilizing data from the Multi‐Institutional Study on Tracheotomy (MIST). Methods A retrospective analysis of patients from the MIST database who underwent surgical or percutaneous tracheotomy between 2013 and 2016 at eight institutions was completed. Unadjusted and adjusted logistic regression analyses were used to assess the impact of obesity on tracheotomy timing and complications. Results Among the 3369 patients who underwent tracheotomy, 41.0% were obese and 21.6% were morbidly obese. BMI was associated with higher rates of prolonged intubation prior to tracheotomy accounting for comorbidities, indication for tracheotomy, institution, and type of tracheostomy ( p = 0.001). Morbidly obese patients (BMI ≥35 kg/m 2 ) experienced a longer duration of intubation compared with patients with a normal BMI (median days intubated [IQR 25%–75%]: 11.0 days [7–17 days] versus 9.0 days [5–14 days]; p < 0.001) but did not have statistically higher rates of return to the operating room within 30 days ( p = 0.12) or mortality ( p = 0.90) on multivariable analysis. This same finding of prolonged intubation was not seen in overweight, nonobese patients when compared with normal BMI patients (median days intubated [IQR 25%–75%]: 10.0 days [6–15 days] versus 10.0 days [6–15 days]; p = 0.36). Conclusion BMI was associated with increased duration of intubation prior to tracheotomy. Although morbidly obese patients had a longer duration of intubation, there were no differences in return to the operating room or mortality within 30 days. Level of Evidence 3 Laryngoscope , 134:4674–4681, 2024
608 Utility 2019 EULAR/ACR SLE criteria to re-classify patients with interstitial pneumonia with autoimmune features as SLE with interstitial lung disease
Martinez-Zayas, Gabriela, Joerns, Elena K. , Karp, David R.

Mayo Clinic

Epidemiology & Outcomes | June 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: A43-A44

10.1136/lupus-2023-lupus21century.39 Get It